Enveric Biosciences Inc. (ENVB) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.46 (-0.68% 1D, market cap $6.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENVB ranks #767 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).
Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $0 in revenue, $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 48.2 (NEUTRAL RANGE)
Capital intensity & 0% operating margin leave 16 pts on the table
While ENVB currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.45) and Max Pain ($1.53) forces dealer call-delta covering toward $13.91.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Enveric Biosciences Inc. (ENVB) slipped -0.68% to $1.46, trading at 2% of its 52-week range ($1.17 – $13.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Enveric Biosciences Inc. (NASDAQ:ENVB) reported favorable outcomes from IND-enabling laboratory studies evaluating its primary drug candidate, EB-003. "These results represent an important milestone in the development of
CAMBRIDGE, Mass., October 21, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurolo
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ENVB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ENVB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Enveric Biosciences Inc. (ENVB) ranks #767 by composite RQD confidence (37/100, grade D-) and #923 by equity capitalization ($6.5M). Within this direct 5-issuer industry benchmark cohort, ENVB leads on earnings valuation at N/A trailing P/E, while ENVB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CNSP currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with ENVB at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENVB
ACTIVE
Enveric Biosciences Inc. | D- | 37/100 | — | — | -35.0% | -0.68% | $6.5M | Benchmark Subject |
| FBLG FibroBiologics Inc. | D- | 40/100 | — | — | -35.0% | -3.99% | $6.3M | /fblg-vs-envb → |
| APRE Aprea Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -8.22% | $6.2M | /apre-vs-envb → |
| CNSP CNS Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +5.77% | $7.0M | /cnsp-vs-envb → |
| XCUR Exicure Inc. | D- | 35/100 | — | — | -35.0% | -8.04% | $6.1M | /xcur-vs-envb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enveric Biosciences Inc. (ENVB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $12.1M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-5.4% YoY). On the balance sheet, ENVB closed FY2025 with $5.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $12.1M | -$8.1M | -$8.1M | $5.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $9.6M | -$7.7M | -$7.7M | $3.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $17.5M | -$14.1M | -$14.1M | — | — |
As of 2026-11-01, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.46 (-0.68% 1D, market cap $6.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENVB ranks #767 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).
Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $0 in revenue, $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ENVB last traded at $1.46 (-0.68% on volume of 29,469 shares), positioning the stock +0.69% above its 50-day simple moving average ($1.45) and -27.72% below its 200-day simple moving average ($2.02). Across its 52-week range of $1.17 to $13.25, ENVB sits at the 2.4% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.28 to $1.64).
Why ENVB Stock slipped -0.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.